The delta2-opioid receptor subtype stimulates phosphoinositide metabolism in mouse periaqueductal gray matter

Life Sciences

Volumn 62, Issue 16, 1998, Pages

  Rodríguez Díaz, Marta ^a   Garzón, Javier ^a   Sánchez Blázquez, Pilar ^a  

^a INSTITUTO CAJAL   (Spain)

Author keywords

Antisense oligodeoxynucleotide; Delta opioid agonists; Delta opioid antagonists; Delta opioid receptor subtypes; Periaqueductal gray matter; Phosphoinositide hydrolysis

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; DELTA OPIATE RECEPTOR; DELTORPHIN[2 DEXTRO ALANINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; INOSITOL PHOSPHATE; N,N DIALLYLTYROSYL 2 METHYLALANYL 2 METHYLALANYLPHENYLALANYLLEUCINE; OPIATE AGONIST; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; ANALGESIC AGENT; BORDETELLA VIRULENCE FACTOR; DELTORPHIN II, ALA(2); DELTORPHIN II, ALA(2)-; ENKEPHALIN; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL; OLIGOPEPTIDE; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOL; TRITIUM;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; IN VITRO STUDY; ISOTOPE LABELING; MALE; MOUSE; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PHOSPHOINOSITIDE METABOLISM; ANIMAL; BIOSYNTHESIS; CLASSIFICATION; DRUG EFFECT; DRUG POTENTIATION; METABOLISM; PHYSIOLOGY; SENSITIVITY AND SPECIFICITY; ULTRASTRUCTURE;

ANALGESICS; ANIMALS; ENKEPHALIN, D-PENICILLAMINE (2,5)-; ENKEPHALINS; GTP-BINDING PROTEINS; INOSITOL; MALE; MICE; OLIGOPEPTIDES; PERIAQUEDUCTAL GRAY; PERTUSSIS TOXIN; PHOSPHATIDYLINOSITOLS; RECEPTORS, OPIOID, DELTA; SENSITIVITY AND SPECIFICITY; TRITIUM; VIRULENCE FACTORS, BORDETELLA;

EID: 0031627404     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00083-6     Document Type: Article

References (20)

1. 1. Q. JIANG, A.E. TAKEMORI, M. SULTANA, P.S. PORTOGHESE, W.D. BOWEN, H.I. MOSBERG and R. PORRECA. J. Pharmacol. Exp. Then 257 1069-1075 (1991).
2. 2. A. MATTIA, T. VANDERAH, H.I. MOSBERG and F. PORRECA. J. Pharmacol. Exp. Ther. 258 583-587 (1991).
3. 3. B. BUZAS, S. IZENWASSER, P.S. PORTOGHESE and B.M. COX. Life Sci. 54 101-106 (1994).
4. 4. P.A. ZAKI, E.J. BILSKY, T.W. VANDERAH, J. LAI, C.J. EVANS and F. PORRECA. Annu. Rev. Pharmacol. Toxicol. 36 379-401 (1996).
5. 5. K. YASUDA, K. RAYNOR, H. KONG, C. BREDER, J. TAKEDA, T. REISINE and G.I. BELL. Proc. Natl. Acad. Sci. USA 90 6736-6740 (1993).
6. 6. J. LAI, E.J. BILSKY, R.B. ROTHMAN and F. PORRECA. Neuro Report, 5 1049-1052 (1994).
7. 7. E.J. BILSKY, R.N. BERNSTEIN, V.J. HRUBY, R.B. ROTHMAN, J. LAI and F. PORRECA. J. Pharmacol. Exp. Ther. 277 491-501 (1996).
8. 8. G.G. ROSSI, W. SU, L. LEVENTHAL, H. SU and G.W. PASTERNAK. Brain Res. 275 176-179 (1997).
9. 9. P. SÁNCHEZ-BLÁZQUEZ, A. GARCÍA-ESPAÑA and J. GARZÓN. J. Pharmacol. Exp. Ther. 280 1423-1431(1997).
10. 10. S.R. CHILDERS. Life Sci. 48 1991-2003 (1991).
11. 11. W. JING, N.M. LEE, H.H. LOH and S.A. THAYER. Mol. Pharmacol. 42 1083-1089 (1992).
12. 12. M.A. CONNOR, A. PLANNER and G. HENDERSON. Regu. Pept. 54 65-66 (1994).
13. 13. D. SMART and D.G. LAMBERT. J. Neurochem. 66 1462-1466 (1996).
14. 14. T. MIYAMAE, N. FUKUSHIMA, Y. MISU and H. UEDA. FEBS Lett. 333 311-314 (1993).
15. 15. R.C. TSU, J.S.C. CHAN and Y.H. WONG. J. Neurochem. 64 2700-2707 (1995).
16. 16. M.D. MATTEUCCI and M.H. CARUTHERS. J. Am. Chem. Soc. 103 3185-3191 (1981).
17. 17. M.J. BERRIDGE, C.P. DOWNES and M.E. HANLEY. Biochem. J. 206 587-595 (1982).
18. 18. P. SÁNCHEZ-BLÁZQUEZ and J. GARZÓN. Eur. J. Pharmacol. 152 357-361 (1988).
19. 19. T. VANDERAH, A.E. TAKEMORI, M. SULTANA, P.S. PORTOGHESE, H.I. MOSBERG, V.J. HRUBY, R.C. HAASETH, T. MATSUNAGA and F. PORRECA European J. Pharmacol. 252 133-137 (1994).
20. 20. J. GARZÓN, A. GARCÍA-ESPAÑA and P. SÁNCHEZ-BLÁZQUEZ. J. Pharmacol. Exp. Ther. 281 549-557 (1997).